APA

Mayerhoefer M. E., Karanikas G., Kletter K., Kiesewetter B., Weber M., Rausch I., Pones M., Simonitsch-Klupp I., Müllauer L., Dolak W., Lukas J. & Raderer M. (20170111). Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. : Clinical nuclear medicine.

Chicago

Mayerhoefer Marius E, Karanikas Georgios, Kletter Kurt, Kiesewetter Barbara, Weber Michael, Rausch Ivo, Pones Matthias, Simonitsch-Klupp Ingrid, Müllauer Leonhard, Dolak Werner, Lukas Julius and Raderer Markus. 20170111. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. : Clinical nuclear medicine.

Harvard

Mayerhoefer M. E., Karanikas G., Kletter K., Kiesewetter B., Weber M., Rausch I., Pones M., Simonitsch-Klupp I., Müllauer L., Dolak W., Lukas J. and Raderer M. (20170111). Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. : Clinical nuclear medicine.

MLA

Mayerhoefer Marius E, Karanikas Georgios, Kletter Kurt, Kiesewetter Barbara, Weber Michael, Rausch Ivo, Pones Matthias, Simonitsch-Klupp Ingrid, Müllauer Leonhard, Dolak Werner, Lukas Julius and Raderer Markus. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. : Clinical nuclear medicine. 20170111.